Non-small cell lung cancer

Last reviewed: 6 May 2023

Last updated: 25 Oct 2022

Non-small cell lung cancer is most common in older adult smokers and ex-smokers. Small tumours in the lung are often asymptomatic, so the majority of patients have either locally advanced or metastatic disease at diagnosis.

Most common presenting symptoms are cough, chest pain, haemoptysis, dyspnoea, and weight loss.

A suspicious lung mass can be biopsied during bronchoscopy or using CT guidance. Staging studies (i.e., CT, PET, mediastinal sampling) are required to determine extent of local or regional disease and to evaluate for metastases.

Treatment depends on stage of disease, histological subtype, molecular genotype, and patient comorbidities. Treatment modalities include surgery, radiotherapy, and chemotherapy, as well as molecular-targeted therapy for specific genotypes and immunotherapy.

Definition

Lung cancer comprises a group of malignant epithelial tumours arising from cells lining the lower respiratory tract. Lung cancer is divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC accounts for more than 80% of all lung cancers.[1] There are three main types of NSCLC (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and these are grouped into further subtypes.

History and exam

Key diagnostic factors

presence of risk factors
cough
dyspnoea
haemoptysis
chest and/or shoulder pain
weight loss

More key diagnostic factors

Other diagnostic factors

male sex
fatigue
pulmonary examination abnormalities
hoarseness
confusion
personality changes
nausea and vomiting
headache
dysphagia
bone pain and/or fractures
weakness, paraesthesias and/or pain in C8/T1 distribution
seizures
cervical or supraclavicular adenopathy
Horner's syndrome
facial swelling
dilated neck or chest/abdominal wall veins
finger clubbing
hypertrophic pulmonary osteoarthropathy

Other diagnostic factors

Risk factors

cigarette smoking
environmental tobacco exposure
chronic obstructive pulmonary disease
family history
radon gas exposure
older age
asbestos exposure

More risk factors

Diagnostic investigations

1st investigations to order

chest x-ray
contrast-enhanced CT scan of lower neck, thorax, and upper abdomen

More 1st investigations to order

Investigations to consider

sputum cytology
bronchoscopy
biopsy
diagnostic thoracentesis and/or pleural biopsy
sampling of the mediastinal lymph nodes: mediastinoscopy and endobronchial ultrasound
video-assisted thoracoscopic surgery (VATS)
thoracoscopy
MRI or CT of brain
MRI of thoracic inlet
PET-CT
bone scan
contrast-enhanced CT liver and adrenals
pulmonary function tests (PFT)
FBC
LFTs
serum calcium
electrolytes and renal function
electrocardiogram and echocardiogram
epidermal growth factor receptor (EGFR) mutation testing
anaplastic lymphoma kinase (ALK) testing
ROS proto-oncogene 1 (ROS1) testing
programmed death-ligand 1 (PD-L1) testing
B-Raf proto-oncogene (BRAF) testing
neurotrophin tyrosine receptor kinase (NTRK) fusion testing
c-Mesenchymal-epithelial transition factor (c-MET) exon 14 (METex14) skipping mutations testing
rearranged during transfection (RET) gene mutations testing
KRAS proto-oncogene (KRAS) point mutations testing

More investigations to consider

Treatment algorithm

ONGOING

stage I and II

stage IIIA

stage IIIB and IIIC

stage III with tumours too extensive for combination chemoradiotherapy or stage IV and suitable for immunotherapy or targeted therapy

stage III with tumours too extensive for combination chemoradiotherapy or stage IV and unsuitable for immunotherapy or targeted therapy (ECOG performance 0-2)

stage III with tumours too extensive for combination chemoradiotherapy or stage IV and unsuitable for immunotherapy or targeted therapy (ECOG performance 3-4)

Contributors

Authors

Alex A. Adjei, MD, PhD, FACP

Chairman, Taussig Cancer Institute

M. Frank Rudy and Margaret Domiter Rudy Distinguished Chair in Translational Cancer Research

Cleveland Clinic

Cleveland

Disclosures

AAA has acted as an uncompensated advisory board member for Swiss Rockets, Merck AG, and Zai Lab.

Dr Fen Wang, MD

Peking University Shenzhen Hospital

Shenzhen

Guangdong

China

Disclosures

FW declares that she has no competing interests

Acknowledgements

Professor Alex A. Adjei and Dr Fen Wang would like to gratefully acknowledge Professor David R. Baldwin, Dr Sanjay Popat, Dr Mick Peake, Dr Chris Kelsey, and Dr Lawrence Marks, previous contributors to this topic.

Disclosures

DRB declares that he has no competing interests. SP has been paid and acted as a consultant to BMS, Eli Lilly, Roche, Takeda, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingelheim, and Tesaro; SP has received research grants from Pierre Fabre, Otsuka, and Boehringer Ingelheim; SP has received assistance for travel from Boehringer Ingelheim, MSD, and Pfizer. MP has received lecture fees from AstraZeneca Pharmaceuticals, Lilly Oncology Ltd, Pierre-Fabre, GSK Ltd, and Roche Pharmaceuticals Ltd; MP has also received educational grants to attend scientific conferences from Roche Pharmaceuticals Ltd and Boehringer Ingelheim Ltd. CK and LM declare that they have no competing interests.

Peer reviewers

Alan Neville, MD

Professor

Assistant Dean

Undergraduate Program

McMaster University

Hamilton

Ontario

Canada

Disclosures

AN declares that he has no competing interests.

James Huang, MD

Assistant Attending Surgeon

Thoracic Service

Memorial Sloan Kettering Cancer Center

New York

Disclosures

JH declares that he has no competing interests.

Siow Ming Lee, PhD, FRCP

Consultant Medical Oncologist

University College Hospital

London

Disclosures

SML declares that he has no competing interests.

Differentials
- Small cell lung cancer
- Metastatic cancer
- Pneumonia/bronchitis
More Differentials
Guidelines
- Lung cancer: diagnosis and management
- Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline
More Guidelines
Patient leaflets
Lung cancer (non-small-cell)
Lung cancer: questions to ask your doctor
More Patient leaflets
Videos
Insertion of intercostal drain, Seldinger technique: animated demonstration
Venepuncture and phlebotomy animated demonstration
More videos
Log in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer

Non-small cell lung cancer

Summary

Definition

History and exam

Key diagnostic factors

Other diagnostic factors

Risk factors

Diagnostic investigations

1st investigations to order

Investigations to consider

Treatment algorithm

stage I and II

stage IIIA

stage IIIB and IIIC

stage III with tumours too extensive for combination chemoradiotherapy or stage IV and suitable for immunotherapy or targeted therapy

stage III with tumours too extensive for combination chemoradiotherapy or stage IV and unsuitable for immunotherapy or targeted therapy (ECOG performance 0-2)

stage III with tumours too extensive for combination chemoradiotherapy or stage IV and unsuitable for immunotherapy or targeted therapy (ECOG performance 3-4)

Contributors

Authors

Alex A. Adjei, MD, PhD, FACP

Disclosures

Dr Fen Wang, MD

Disclosures

Acknowledgements

Disclosures

Peer reviewers

Alan Neville, MD

Disclosures

James Huang, MD

Disclosures

Siow Ming Lee, PhD, FRCP

Disclosures

Differentials

Guidelines

Patient leaflets

Videos

Log in or subscribe to access all of BMJ Best Practice

Log in or subscribe to access all of BMJ Best Practice

Log in to access all of BMJ Best Practice